JP2024502235A5 - - Google Patents

Info

Publication number
JP2024502235A5
JP2024502235A5 JP2023537297A JP2023537297A JP2024502235A5 JP 2024502235 A5 JP2024502235 A5 JP 2024502235A5 JP 2023537297 A JP2023537297 A JP 2023537297A JP 2023537297 A JP2023537297 A JP 2023537297A JP 2024502235 A5 JP2024502235 A5 JP 2024502235A5
Authority
JP
Japan
Prior art keywords
acid sequence
seq
mage
amino acid
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023537297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502235A (ja
JP7882852B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/064504 external-priority patent/WO2022140321A2/en
Publication of JP2024502235A publication Critical patent/JP2024502235A/ja
Publication of JP2024502235A5 publication Critical patent/JP2024502235A5/ja
Application granted granted Critical
Publication of JP7882852B2 publication Critical patent/JP7882852B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023537297A 2020-12-22 2021-12-21 Mage-b2特異的t細胞受容体 Active JP7882852B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063129447P 2020-12-22 2020-12-22
US63/129,447 2020-12-22
PCT/US2021/064504 WO2022140321A2 (en) 2020-12-22 2021-12-21 Mage-b2-specific t-cell receptors

Publications (3)

Publication Number Publication Date
JP2024502235A JP2024502235A (ja) 2024-01-18
JP2024502235A5 true JP2024502235A5 (cg-RX-API-DMAC7.html) 2024-12-27
JP7882852B2 JP7882852B2 (ja) 2026-06-30

Family

ID=79730149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537297A Active JP7882852B2 (ja) 2020-12-22 2021-12-21 Mage-b2特異的t細胞受容体

Country Status (7)

Country Link
US (1) US20240100162A1 (cg-RX-API-DMAC7.html)
EP (1) EP4267173A2 (cg-RX-API-DMAC7.html)
JP (1) JP7882852B2 (cg-RX-API-DMAC7.html)
AU (1) AU2021410689A1 (cg-RX-API-DMAC7.html)
CA (1) CA3205810A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023007519A (cg-RX-API-DMAC7.html)
WO (1) WO2022140321A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024137652A2 (en) * 2022-12-20 2024-06-27 Abata Therapeutics, Inc. Cell therapies for type 1 diabetes
EP4750807A1 (en) * 2023-07-27 2026-06-03 Immatics Biotechnologies GmbH Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
EP4750806A1 (en) * 2023-07-27 2026-06-03 Immatics Biotechnologies GmbH Antigen binding proteins against mageb2
WO2026025031A1 (en) * 2024-07-26 2026-01-29 Modernatx, Inc. Mrna encoding mageb2 tcer molecule

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010126766A1 (en) 2009-04-30 2010-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
GB201417803D0 (en) * 2014-10-08 2014-11-19 Adaptimmune Ltd T cell receptors
MX2018012265A (es) * 2016-04-08 2019-02-07 Adaptimmune Ltd Receptores de celulas t.
KR20190065189A (ko) * 2016-04-08 2019-06-11 어댑티뮨 리미티드 T 세포 수용체
US20210340201A1 (en) * 2018-08-22 2021-11-04 Fred Hutchinson Cancer Research Center Immunotherapy targeting kras or her2 antigens
US20220213167A1 (en) * 2019-05-03 2022-07-07 Gigamune, Inc. Engineered cells expressing anti-tumor t cell receptors and methods of use thereof
AU2020442490A1 (en) 2020-04-15 2022-11-17 Amgen Inc. Process for generating genetically engineered autologous T cells

Similar Documents

Publication Publication Date Title
JP6612963B2 (ja) 腫瘍抗原を直接認識するために組換えt細胞レセプターを使用するための組成物及び方法
CN108395479B (zh) 一种有关kras基因突变的t细胞受体
Kannagi et al. Target epitope in the Tax protein of human T-cell leukemia virus type I recognized by class I major histocompatibility complex-restricted cytotoxic T cells
JP2023106599A5 (cg-RX-API-DMAC7.html)
JP2019506843A5 (cg-RX-API-DMAC7.html)
JP2021505136A5 (cg-RX-API-DMAC7.html)
KR20230079259A (ko) Kras 돌연변이 특이적 t세포 수용체의 스크리닝 및 항종양 용도
CN110357953B (zh) 识别人巨细胞病毒pp65抗原的TCR
EP2504358B1 (en) T cell receptors specific for immunodominant ctl epitopes of hcv
JP2010516758A5 (cg-RX-API-DMAC7.html)
JP2022538148A5 (cg-RX-API-DMAC7.html)
US20240327490A1 (en) Sars-cov-2-specific t cell receptors and related materials and methods of use
AU2022283277A9 (en) T cell receptors targeting ras mutations and uses thereof
JP2022523024A5 (cg-RX-API-DMAC7.html)
Shimizu et al. Fine structure of a virus-encoded helper T-cell epitope expressed on FBL-3 tumor cells
CN114349847B (zh) 靶向新型冠状病毒rna依赖性rna聚合酶的特异性tcr
CN119053337A (zh) 癌症疫苗及其使用方法
JP2023540123A5 (cg-RX-API-DMAC7.html)
JPH04505019A (ja) ガンマインターフェロンのポリペプチド性阻害剤
JP2024534499A5 (cg-RX-API-DMAC7.html)
JP7851611B2 (ja) ループスを処置するための組成物及び方法
CA2660178C (en) Promiscuous her-2/neu cd4 t cell epitopes
JP2023535366A5 (cg-RX-API-DMAC7.html)
Balog et al. Nef: a pleiotropic modulator of primate lentivirus infectivity and pathogenesis
WO2026040998A1 (zh) Tp53突变体表位肽和特异性t细胞受体及其应用